MOR

MorphoSys (MOR)

MorphoSys AG

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MOR

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/20	15 : 47	Business Wire	MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders	NASDAQ:MOR	MorphoSys AG
2024/06/11	00 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/06/07	05 : 36	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/06/05	23 : 22	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/06/05	05 : 06	Edgar (US Regulatory)	Form SC 14D9/A - Solicitation, recommendation statements: [Amend]	NASDAQ:MOR	MorphoSys AG
2024/06/04	23 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/31	23 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/29	23 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/28	23 : 16	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/24	23 : 13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/24	03 : 19	Edgar (US Regulatory)	Form SC 14D9/A - Solicitation, recommendation statements: [Amend]	NASDAQ:MOR	MorphoSys AG
2024/05/23	23 : 11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/23	22 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/21	23 : 07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/17	23 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/17	23 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/17	05 : 43	Edgar (US Regulatory)	Form SC 14D9/A - Solicitation, recommendation statements: [Amend]	NASDAQ:MOR	MorphoSys AG
2024/05/16	23 : 11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/15	23 : 09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/05/13	23 : 19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOR	MorphoSys AG
2024/04/30	05 : 01	Business Wire	MorphoSys AG Reports First Quarter 2024 Financial Results	NASDAQ:MOR	MorphoSys AG
2024/04/11	21 : 39	Business Wire	MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis	NASDAQ:MOR	MorphoSys AG
2024/03/14	05 : 02	Business Wire	MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:MOR	MorphoSys AG
2024/02/06	20 : 14	IH Market News	Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More	NASDAQ:MOR	MorphoSys AG
2023/12/11	09 : 31	Business Wire	MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study	NASDAQ:MOR	MorphoSys AG
2023/11/21	07 : 19	Dow Jones News	MorphoSys Trial for Blood-Cancer Treatment Reaches Primary Endpoint	NASDAQ:MOR	MorphoSys AG
2023/11/21	06 : 30	Business Wire	MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction	NASDAQ:MOR	MorphoSys AG
2023/11/16	06 : 01	Business Wire	MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results	NASDAQ:MOR	MorphoSys AG
2023/08/10	05 : 01	Business Wire	MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results	NASDAQ:MOR	MorphoSys AG
2023/05/04	05 : 01	Business Wire	MorphoSys AG Reports First Quarter 2023 Financial Results	NASDAQ:MOR	MorphoSys AG